PAK1 and metabolic syndrome: The second and third ranks belonged to the papers entitled “Dissecting the association between Metabolic Syndrome and Prostate Cancer” (AAS = 393) and “Liposome-mediated delivery of the p21 activated kinase-1 (PAK-1) inhibitor IPA-3 limits prostate tumor growth in vivo”, respectively (ASS = 202).